Novartis AG (TSX:NVS)
30.47
+0.19 (0.63%)
Nov 20, 2026, 10:38 AM EST
Novartis AG Employees
Novartis AG had 75,267 employees as of December 31, 2025. The number of employees decreased by 616 or 0.81% compared to the previous year.
Employees
75,267
Change (1Y)
-616
Growth (1Y)
-0.81%
Revenue / Employee
1.08M CAD
Profits / Employee
189.20K CAD
Market Cap
410.33B
Employees Chart
| Date | Employees | Change (1Y) | Growth (1Y) |
|---|---|---|---|
| Dec 31, 2025 | 75,267 | -616 | -0.81% |
| Dec 31, 2024 | 75,883 | -174 | -0.23% |
| Dec 31, 2023 | 76,057 | -25,646 | -25.22% |
| Dec 31, 2022 | 101,703 | -2,620 | -2.51% |
| Dec 31, 2021 | 104,323 | -1,471 | -1.39% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Related Stocks
| Company Name | Employees |
|---|---|
| Extendicare | 23,500 |
| Sienna Senior Living | 15,000 |
| Apotex Health | 6,000 |
| Curaleaf Holdings | 5,554 |
| Green Thumb Industries | 5,000 |
| WELL Health Technologies | 1,507 |
| Knight Therapeutics | 830 |
| Vireo Growth | 612 |
Novartis AG News
- 20 hours ago - Novartis Reaffirms Sales Targets as Drug Trial Results and FDA Talks Loom - MarketBeat
- 21 hours ago - Novartis Says AI Is Speeding Drug Discovery and Trials, but Clinical Payoff Remains Unproven - MarketBeat
- 1 day ago - Watch CNBC's full interview with Novartis CEO Vas Narasimhan - CNBC
- 1 day ago - Novartis CEO Vas Narasimhan on Anthropic IPO: I'm incredibly proud, and it's a very exciting day - CNBC
- 1 day ago - Novartis Targets 5% Annual Sales Growth Through 2031 Despite Patent Expirations - MarketBeat
- 1 day ago - Novartis AG Projects +5% cc1 Sales CAGR Through 2031 and Upgrades Peak Sales Guidance for Key Brands - Nasdaq
- 1 day ago - Novartis AG Transcript: Meet Novartis Management 2026 Part 3 - Transcripts
- 1 day ago - Novartis AG Press release: FY 2026 - Filings